Abstract: This disclosure is directed to compositions comprised of retinaldehyde, one or more skin conditioning agents, and, optionally, one or more additional retinoids. This disclosure is directed. Embodiments are also directed to compositions comprised of retinaldehyde, one or more peptides, one or more skin conditioning agents, one or more calcium containing agents, and, optionally, one or more additional retinoids. Embodiments are also directed to compositions comprised of retinaldehyde, one or more peptides, one or more skin conditioning agents, one or more calcium containing agents, and, optionally, one or more additional retinoids. Additional embodiments disclose methods for treating the skin wherein a characteristic of the skin is improved, the characteristics include firmness, elasticity, fine lines and wrinkles, skin texture, dullness, dyschromia, skin tone, reduction or elimination of acne, and any combination thereof.

Abstract: The present invention relates to a method for treating skin afflictions in a subject comprising a step of administering said subject with a therapeutically effective amount of small extracellular vesicles (sEV) comprising CD98hc. Inventors have demonstrated that healthy dermal fibroblasts produced and secreted EVs bearing characteristic of exosome-like small EVs (sEVs). They have shown that CD98hc was present at the surface of sEVs, transferred and stabilized at the plasma membrane of recipient cells. They observed that the transferred protein was functional both in vitro and in vivo. Furthermore, injection of sEVs in epidermal CD98hc KO mice exhibiting wound healing defect rescued wound closure in vivo. Thus, their findings reveal that CD98hc contained in EVs could potentially be used in vivo to treat and improve multiple skin afflictions by allowing protein rescue.

Abstract: Nanoparticles including tacrolimus, and a method for providing nanoparticles including tacrolimus as well as to nanoparticles including tacrolimus that are obtainable by said method. Also relates to the nanoparticles including tacrolimus for use as a medicament. Further relates to a mucoadhesive buccal film containing the nanoparticles including tacrolimus and the mucoadhesive buccal film for use as a medicament, especially in pediatric patients.

Abstract: This disclosure provides a dry powder formulation of free amino acids with an acceptable and even good taste profile.

Abstract: Disclosed is a composition comprising a plurality of active botanical ingredients, each predominantly associated with an in-use beneficial effect on an animate or inanimate substrate, where said composition comprises: (i) a first aqueous extract of a material derived from a first plant, said first extract comprising a first amount of a first active botanical ingredient; (ii) a second aqueous extract of a material derived from a second plant whose genus is not the same as the first plant, said second extract comprising a first amount of a second active botanical ingredient; (iii) an additional amount of said first active botanical ingredient; and (iv) an additional amount of said second active botanical ingredient; where each said additional amount is included by spiking said composition or the corresponding aqueous extract selectively with said first and said second active botanical ingredients, such that ratio of said first amount of said first active botanical ingredient to its corresponding additional amou

Abstract: The present invention relates to avobenzone-dendrimer conjugates comprising: a polyamide dendrimer conjugated with 1 to 18 units of avobenzone. Also disclosed are sunscreen formulations comprising an avobenzone-dendrimer conjugate and a dermatologically acceptable vehicle.

Abstract: The present invention relates to a method for in situ preparation of cyano-bridged coordination polymers as metal nanoparticles within a biocompatible reverse micellar system by mixing at least two reverse micellar systems, each one containing at least one metal salt precursor. The invention also relates to the stabilization of theses nanoparticles by using a biocompatible reverse micellar system. This system takes part of the synthesis as a nanoreactor which comprises at least an acylglycerol, a sterol, lecithin, ethanol and water for the preparation of stable cyano-bridged metal nanoparticles without any use of additional stabilizer agent.

Abstract: Cosmetic lipid mixture of a) octyldodecanol and b) hydrogenated rapeseed oil in a weight ratio of 7:1 to 1:1, process for the production of the lipid mixture, and lipstick containing this lipid mixture.

Abstract: An oil-in-water-type emulsion cosmetic contains an ultraviolet ray scattering agent and which has preparation stability in a system where a water-soluble alkyl-substituted polysaccharide derivative and another emulsifying agent coexist is further improved. The oil-in-water-type emulsion cosmetic containing (A) a water-soluble alkyl-substituted polysaccharide derivative, (B) a nonionic surfactant and (C) an ultraviolet ray scattering agent, wherein the blend ratio [(A)/(B)] of the water-soluble alkyl-substituted polysaccharide derivative (A) to the nonionic surfactant (B) is 1.54 or less, and the blend ratio [(A)/(C)] of the water-soluble alkyl-substituted polysaccharide derivative (A) to the ultraviolet ray scattering agent (C) is 0.02 or less.

Abstract: An oil-in-water type emulsion solid cosmetic that causes “adhesion” similar to that of a water-in-oil type emulsion solid cosmetic including wax, while having freshness and a moisturizing effect of an oil-in-water type emulsion substance. An oil-in-water type emulsion solid cosmetic contains (A) at least one hydrophilic thickening agent selected from the group consisting of gellan gum, agar, and copolymers including 2-acrylamide-2-methyl propane sulfonic acid, (B) a higher alcohol, (C) a surfactant, (D) water, and (E) an oil component, wherein the ratio between the blending amount of the (A) hydrophilic thickening agent and the total blending amount of the (B) higher alcohol and the (C) surfactant falls within the range of 3:1-1:9.

Abstract: An antimicrobial composition containing: a component (A) that is at least one selected from the group consisting of 1,2-alkanediols having an alkyl group having 6 to 8 carbons and monoalkyl glyceryl ethers having an alkyl group having 6 to 8 carbons; and a component (B) that is at least one selected from the group consisting of tripropylene glycol, 2-methyl-1,3-propanediol, and 3-methyl-1,3-butanediol and a cosmetic containing the antimicrobial composition.

Abstract: Ready to use liquid formulations of diclofenac potassium are disclosed which are particularly well suited for packaging in stick-packs.

Abstract: The present disclosure provides topical compositions of rofecoxib and methods of making said compositions. The present disclosure also provides methods of using topical compositions of rofecoxib to treat inflammation.

Abstract: Compositions and methods for the treatment of hair growth and the prevention of hair loss.

Abstract: The present invention relates to dentifrice compositions comprising spherical, anhydrous, amorphous, silica gel particles having a pore volume of less than 0.1 ml/g and an orally acceptable carrier. Such compositions can effectively clean, polish and remove stains from the surface of teeth or dentures without a high degree of abrasion thereby reducing scratching and damage to the tooth or denture surface. Such compositions thereby provide superior cleaning, polishing, gentle stain removal and whitening of tooth surfaces or dentures.

Abstract: Provided are methods and compositions for treatment of tinnitus. The method comprises administration of therapeutically effective amount of oxytocin, which may be present with a thickener, and may be delivered to the back of the nasal cavity in a suitable form. Compositions of oxytocin for intranasal delivery and sprayable unit compositions of oxytocin are also provided.

Abstract: The present invention relates to transdermal drug delivery system of pharmaceutical compositions, which have a satisfactory in-vitro performance and good bioavailability. In particular, the transdermal pharmaceutical composition of clobazam in the present invention includes a micro-emulsion in liquid or semi solid form, in a dosage form adapted for transdermal delivery (e.g., transdermal patch) for treatment of certain types of epilepsy and anxiety for continues application.

Abstract: The method for making a nanoemulsion is described. The method uses a neutralized fatty acid and does not require traditional surfactant in order to yield stable nanoemulsion having a diameter from 70 to 550 nm.

Abstract: A method of preventing contact allergies includes using at least one amphoteric chelating agent which includes a complex based on aluminium and on ethylenediaminetetraacetic acid or the trisodium salt thereof, having the general formula [Al(Y)Bn]c?Dc with B being OH?, BO2? or H+, Y being a tetracarboxylate which can be protonated four times to form ethylenediaminetetraacetic acid, n being an integer equal to 0, 1, 2 or 3, D being a counterion, preferably Na+, c being an integer equal to 0, 1, 2 or 3 and c? being a relative number having the same absolute value as c. A device, a part of which includes the amphoteric chelating agent, is also described.

Abstract: An emulsion cosmetic maintains a concealing ability, allows light in a long wavelength region to transmit efficiently (i.e., an excellent red light selective transmit function), is spread easily, wherein a powder likeness cannot be felt upon use, and provides a natural finish when applied onto the skin. A titanium dioxide powder therefore is composed of particles having an apparent average particle diameter of 100 nm or more and less than 500 nm, an average crystallite diameter of 15 to 30 nm as measured by a X-ray diffraction method and a specific surface area of 10 to 30 m2/g, and each has a shape with radially projected needle-like projections are coagulated, and has a ratio of a longer axis to a shorter axis (i.e., a (longer axis)/(shorter axis) ratio) in the shape of 1.0 to 2.5. The emulsion cosmetic contains 0.1 to 25% by mass of the titanium dioxide powder, 0.1 to 5% by mass of disteardimonium hectorite and 0.1 to 8% by mass of a silicone surfactant.